Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Pharma and Pantherna Therapeutics Enter New Technology Evaluation Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Astellas Pharma and Pantherna Therapeutics Enter New Technology Evaluation Agreement

Pantherna's mRNA platform & Astellas' drug discovery capabilities will be combined to generate mRNA-based regenerative medicine programs.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation).
 
This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.
 
Pantherna owns a proprietary platform of unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body. Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approach. Astellas will be responsible for providing drug discovery ideas, preparing candidate compounds for technology evaluation, and performing research aimed at developing this therapeutic modality, while Pantherna will be responsible for providing technical information and development support.
 
“We are excited about this expansion of our collaboration with Astellas,” said Pantherna’s chief executive officer, Klaus Giese, Ph.D. “We feel honored that Astellas, as a leading pharmaceutical company, has underscored their interest in leveraging the unique aspects of our proprietary therapeutic mRNA technology.”
 
“Through this agreement, which expands the scope of our collaboration with Pantherna, we will create innovative regenerative medicine programs for new target organ, and we expect that we will be able to thereby expand the treatment options for diseases with high unmet medical needs.” said Taiji Sawamoto, Ph.D., executive vice president, Applied Research & Operations, at Astellas. “The collaboration with Pantherna is an initiative which synergistically integrates Astellas’ expertise with mRNA as a therapeutic modality and its capabilities cultivated in the research field of direct reprogramming, and will promote the development of next-generation treatments using a new modality/technology based on the Focus Area approach strategy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics